Successful treatment of juvenile xanthogranuloma using bevacizumab.
Juvenile xanthogranuloma (JXG) is an uncommon non-Langerhans cell histiocytic disorder that occurs predominantly in infants. Traditional treatment of ocular JXG involves the administration of topical or local corticosteroids. We treated 2 children with JXG refractory to local corticosteroid therapy with off-label intraocular bevacizumab. To our knowledge, this is the first report of successful use of bevacizumab for ocular JXG.
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida.
Noy
N
Ashkenazy
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: chenry2@med.miami.edu.
Christopher R
CR
Henry
Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan.
Ashkan M
AM
Abbey
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida.
Craig A
CA
McKeown
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida.
Audina M
AM
Berrocal
Murray Ocular Oncology and Retina, Miami.
Timothy G
TG
Murray
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D002675:Child, Preschool; D003316:Corneal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006068:Gonioscopy; D006801:Humans; D007223:Infant; D056965:Injections, Intraocular; D058449:Intravitreal Injections; D007499:Iris Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D058475:Tenon Capsule / Q000187:drug effects; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014972:Xanthogranuloma, Juvenile / Q000175:diagnosis / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab